Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study
US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.
You may also be interested in...
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.
Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.
US FDA to assess whether consumers and healthcare professionals can detect and report false or misleading promotions; Bad Ad program could be expanded to consumers.